http://www.zibb.com/healthcare/theme/cq/Dyax+Corporation Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Thu, 29 Oct 2009 15:02:59 GMTThu, 29 Oct 2009 15:02:59 GMT608831http://www.zibb.com/healthcare/theme/cq/Dyax+Corporation http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://seekingalpha.com/article/169841-biomed-news-bytes-dyax-human-genome-sciences-aldagen?source=feedMike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent,http://seekingalpha.com/article/169841-biomed-news-bytes-dyax-human-genome-sciences-aldagen?source=feedDyax CorporationThu, 29 Oct 2009 15:02:59 GMThttp://finance.yahoo.com/news/Dyax-receives-15-million-apf-2273042103.html?x=0&.v=1CAMBRIDGE, Mass. (AP) -- Biotechnology company Dyax Corp. said Wednesday it received a $1.5 million payment as Eli Lilly & Co. moved a potential leukemia treatmenthttp://finance.yahoo.com/news/Dyax-receives-15-million-apf-2273042103.html?x=0&.v=1Dyax CorporationWed, 26 Aug 2009 17:53:01 GMThttp://www.biospace.com/news_story.aspx?StoryID=152758&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Ivana Magovcevic-Liebisch, Executive Vice President of Administration and General Counsel of Dyax, will present at the 29th Annual Canaccord Adams Globalhttp://www.biospace.com/news_story.aspx?StoryID=152758&full=1Dyax CorporationMon, 10 Aug 2009 12:00:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=52106090Dyax is reducing its staff by 60 positions to focus resources on the approval and commercialization of its lead candidate, DX-88 for hereditary angioedema (HAE). The company also ehttp://www.genengnews.com/news/bnitem.aspx?name=52106090Dyax CorporationTue, 31 Mar 2009 00:00:00 GMThttp://www.bizjournals.com/boston/stories/2009/03/30/daily24.html?ana=from_rssDyax Corp. is eliminating 60 positions — or roughly 36 percent of its staff — from various departments within the company to focus its resources on the commercialization of its lead product candidate.http://www.bizjournals.com/boston/stories/2009/03/30/daily24.html?ana=from_rssDyax CorporationMon, 30 Mar 2009 21:48:12 GMThttp://feeds.bizjournals.com/~r/vertical_36/~3/437054380/daily38.htmlThe Cambridge, Mass.-based biopharmaceutical company (Nasdaq: DYAX) said it had entered into the agreement, known as a committed equity financing facility, under which it could sell up to $50 million of its common stock to Azimuth Opportunity Ltd. over 18 months.http://feeds.bizjournals.com/~r/vertical_36/~3/437054380/daily38.htmlDyax CorporationThu, 30 Oct 2008 15:28:30 GMThttp://us.rd.yahoo.com/finance/external/trsa/rss/SIG=12muujb1c/*http://seekingalpha.com/article/102500-amedisys-inc-q3-2008-earnings-call-transcript?source=yahooThanks. Good morning and thank you for joining us today for Amedisys investor conference call to discuss this morning’s third quarter 2008 earnings announcement and related matters. By now you should receive a copy of our earnings press release.http://us.rd.yahoo.com/finance/external/trsa/rss/SIG=12muujb1c/*http://seekingalpha.com/article/102500-amedisys-inc-q3-2008-earnings-call-transcript?source=yahooDyax CorporationTue, 28 Oct 2008 23:48:14 GMThttp://rss.feedsportal.com/c/506/f/6822/s/208e0e5/l/0L0Sbioportfolio0O0Ccgi0Ebin0Cdialogserver0Bexe0DCMD0Fhit0BdisplayMdoc0GID0F19127770GHITNO0F140GMSIZE0F10A0A0A0GLANGUAGE0Fen0GFILE0Fdoc0BNEWSFEED0GSAVEQUERY0A0A0Fbiotechnology0J20Apharmaceutical0GSAVEPROP0A0A0FL0J3den0GSAVEDB0Fnews0GSAVEORGANISE0ICODED0FR0J3adate0GR0F19127770GTHISHREF0Fhttp0J3a0C0Cc0Bmoreover0N0Cclick0Chere0Bpl0J3fz16260A468490J26amp0J3bz0J3d950A2422730GTHEHOST0Fsite0Kd0Bmoreover0Bcom/story01.htmBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://rss.feedsportal.com/c/506/f/6822/s/208e0e5/l/0L0Sbioportfolio0O0Ccgi0Ebin0Cdialogserver0Bexe0DCMD0Fhit0BdisplayMdoc0GID0F19127770GHITNO0F140GMSIZE0F10A0A0A0GLANGUAGE0Fen0GFILE0Fdoc0BNEWSFEED0GSAVEQUERY0A0A0Fbiotechnology0J20Apharmaceutical0GSAVEPROP0A0A0FL0J3den0GSAVEDB0Fnews0GSAVEORGANISE0ICODED0FR0J3adate0GR0F19127770GTHISHREF0Fhttp0J3a0C0Cc0Bmoreover0N0Cclick0Chere0Bpl0J3fz16260A468490J26amp0J3bz0J3d950A2422730GTHEHOST0Fsite0Kd0Bmoreover0Bcom/story01.htmDyax CorporationFri, 03 Oct 2008 23:50:15 GMThttp://www.contractpharma.com/news/2008/09/24/dyax_submits_hae_blaDyax Corp. has completed its BLA for DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). Dyax has requested Priority Review; if granted, this would set a target date of six months from receipt of the completed submission for the FDA to take action on the application.http://www.contractpharma.com/news/2008/09/24/dyax_submits_hae_blaDyax CorporationWed, 24 Sep 2008 12:36:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=DE6C7E20-B6CE-4D96-AADD-70F0C44E7635Sanofi-Aventis has acquired Australia-based Symbion CP Holdings for A$560 million.http://www.pharmaceutical-business-review.com/article_news.asp?guid=DE6C7E20-B6CE-4D96-AADD-70F0C44E7635Dyax CorporationTue, 02 Sep 2008 13:14:00 GMThttp://www.forbes.com/2008/08/18/dyax-ecallantide-update-markets-equity-cx_lal_0818markets25.html?feed=rss_business_healthcareShares of the small biotech jumped on positive results of its new inflammatory disease treatment.http://www.forbes.com/2008/08/18/dyax-ecallantide-update-markets-equity-cx_lal_0818markets25.html?feed=rss_business_healthcareDyax CorporationMon, 18 Aug 2008 20:20:00 GMThttp://www.masshightech.com/stories/2008/04/28/daily1-Dyax-ponders-closing-Belgium-RD-site.htmlThe closure of the research operation would enable Dyax (Nasdaq: DYAX) to consolidate its discovery and preclinical programs at its headquarters in Cambridge, company officials said. The weakening U.S. dollar has contributed to a rise in operating costs in Europe.http://www.masshightech.com/stories/2008/04/28/daily1-Dyax-ponders-closing-Belgium-RD-site.htmlDyax CorporationMon, 28 Apr 2008 14:47:13 GMThttp://www.cnbc.com/id/23182813/site/14081545?__source=yahoo|headline|quote|text|&par=yahooTaking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.http://www.cnbc.com/id/23182813/site/14081545?__source=yahoo|headline|quote|text|&par=yahooDyax CorporationFri, 15 Feb 2008 14:41:46 GMThttp://www.pharmacychoice.com/news/article.cfm?Article_ID=345372CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 18, 2009--Dyax Corp. (NASDAQ: DYAX) announced today that it has amended its existing loan agreement with Cowen Healthcare Royalty Partners, L.P. (?CHRP?) to receive an additional loan of $15 million (the ?Tranche B Loan?).http://www.pharmacychoice.com/news/article.cfm?Article_ID=345372Dyax Corporationhttp://www.bectondickinson.com/contentmanager/b_article.asp?Item_ID=21380&ContentType_ID=1&BusinessCode=20001&d=&s=&dTitle=&dc=&dcTitle=Franklin Lakes, NJ and Cambridge, MA --June 13, 2001-- BD Biosciences (BDB), a division of BD (Becton, Dickinson and Company) (NYSE:BDX), and Dyax Corp.http://www.bectondickinson.com/contentmanager/b_article.asp?Item_ID=21380&ContentType_ID=1&BusinessCode=20001&d=&s=&dTitle=&dc=&dcTitle=Dyax Corporationhttp://seekingalpha.com/article/169595-dyax-corp-q3-2009-earnings-call-transcript?source=feedDyax Corp. (DYAX)Q3 2009 Earnings CallOctober 28, 2009 10:00 am ETCompletehttp://seekingalpha.com/article/169595-dyax-corp-q3-2009-earnings-call-transcript?source=feedDyax CorporationWed, 28 Oct 2009 19:40:25 GMThttp://www.biospace.com/news_story.aspx?StoryID=147437&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) today announced that it has agreed to sell 7,425,743 shares of its common stock at a price of $2.02 per share in an underwritten public offering with no warrants.http://www.biospace.com/news_story.aspx?StoryID=147437&full=1Dyax CorporationThu, 25 Jun 2009 12:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=144375&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Companys submission in response to the FDAs March 2009 Complete Response letter which outlined requirements for approval of DX-88 for thehttp://www.biospace.com/news_story.aspx?StoryID=144375&full=1Dyax CorporationMon, 08 Jun 2009 12:00:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=E3D15FD1-7C90-44CD-85CD-B586BD3C784ASanofi-Aventis has announced that the Japanese Ministry of Health, Labor and Welfare has granted an approval for use of Taxotere injection in prostate cancer.http://www.pharmaceutical-business-review.com/article_news.asp?guid=E3D15FD1-7C90-44CD-85CD-B586BD3C784ADyax CorporationTue, 02 Sep 2008 13:13:00 GMThttp://www.forbes.com/2008/08/18/dyax-ecallantide-angioedema-markets-equity-cx_lal_0818markets14.html?feed=rss_business_healthcareBiotech's shares shoot up after positive results for treatment of rare inflammatory condition.http://www.forbes.com/2008/08/18/dyax-ecallantide-angioedema-markets-equity-cx_lal_0818markets14.html?feed=rss_business_healthcareDyax CorporationMon, 18 Aug 2008 17:45:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=800FC7F8-BD47-4A84-99FC-244F66EF3A70US-based biotechnology company Dyax has appointed George Migausky as its new executive vice president and CFO following the retirement of Steve Galliker.http://www.pharmaceutical-business-review.com/article_news.asp?guid=800FC7F8-BD47-4A84-99FC-244F66EF3A70Dyax CorporationFri, 08 Aug 2008 13:56:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=38781942Dyax entered into an exclusive negotiation period with Dompé Farmaceutici for a European license to DX-88 in angioedema indications including hereditary angioedema (HAE), forhttp://www.genengnews.com/news/bnitem.aspx?name=38781942Dyax CorporationTue, 15 Jul 2008 00:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=107164&full=1Aug 18 (Reuters) - Biopharmaceutical company Dyax Corp said its product candidate for the treatment of hereditary angioedema (HAE) met the main goal of a late-stage clinical trial, sending its shares up 26 percent.http://www.biospace.com/news_story.aspx?StoryID=107164&full=1Dyax CorporationFri, 15 Aug 2008 12:00:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=E5EA6A89-4605-40C9-AF51-0D8BD53BABFBSanofi-Aventis has announced that the FDA has assigned priority review status for its new drug application for Multaq.http://www.pharmaceutical-business-review.com/article_news.asp?guid=E5EA6A89-4605-40C9-AF51-0D8BD53BABFBDyax CorporationTue, 12 Aug 2008 07:02:00 GMThttp://www.pharmaceutical-business-review.com/article_news.asp?guid=C42EC158-8113-4163-AC0F-EEE7CA2ACA78Dyax has treated the final patient in its second Phase III, 96-patient trial of DX-88, known as Edema4, for the treatment of acute attacks of hereditary angioedema.http://www.pharmaceutical-business-review.com/article_news.asp?guid=C42EC158-8113-4163-AC0F-EEE7CA2ACA78Dyax CorporationWed, 25 Jun 2008 15:42:00 GMT